Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Study of Oral Fluorescite to Confirm the Authenticity of Point of Care Urine Samples

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04071080
Recruitment Status : Completed
First Posted : August 28, 2019
Last Update Posted : January 6, 2020
Sponsor:
Collaborator:
Medicor Research Inc.
Information provided by (Responsible Party):
UpTru Inc.

Brief Summary:
During this study, participants will ingest 100 mg of fluorescein disodium or a placebo (no drug) mixed in GatoradeTM. Participants will then provide a urine sample after 10, 15, 20 or 30 minutes to see if the investigator can detect fluorescein fluorescence (light) in the urine.

Condition or disease Intervention/treatment Phase
Urine Sample Authenticity Drug: fluorescein sodium Drug: Placebo Phase 1

Detailed Description:

Every year, millions of dollars are spent on urine drug testing. Urine samples are generally provided in an unwitnessed fashion. Only a small percentage of samples involve direct observation of urination. The authenticity of the provided sample greatly affects its clinical utility and/or the validity of the test results. Direct observation of urination can be unpleasant and humiliating for people. For the institution, there are increased costs (for example, staff, insurance) and risks regarding impropriety when direct observation is utilized.

Participants are being asked to take part in a research study of an approved drug called FluoresciteTM. FluoresciteTM is an intravenous drug (administered into a vein) that has been approved by Health Canada. The active ingredient in FluoresciteTM is fluorescein disodium (10% fluorescein disodium in sterile water).

Fluorescein disodium has been used medically for over fifty years. It is a fluorophore (emits light, similar to a yellow glowstick) that is most commonly used in ophthalmology (the study and treatment of disorders and diseases of the eye). It is currently used in angiography (to view blood vessels), or topically for staining the eye's cornea. FluoresciteTM or fluorescein disodium has not been approved by Health Canada for oral administration.

During this study, participants will ingest 100 mg of fluorescein disodium or a placebo (no drug) mixed in GatoradeTM. The Investigator will then ask the participant to provide a urine sample after 10, 15, 20 or 30 minutes to see if he can detect fluorescence (light) in the urine.

The purpose of this study is to:

  • Develop a new standardized protocol for urine sampling that will increase sample authenticity and make the situation between the patient/physician more pleasant.
  • To evaluate the safety and tolerability of orally ingested fluorescein disodium.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Screening
Official Title: A Phase I, Randomized, Double-blind, Placebo-controlled Study of Oral Fluorescite to Confirm the Authenticity of Point of Care Urine Samples
Actual Study Start Date : August 22, 2019
Actual Primary Completion Date : November 28, 2019
Actual Study Completion Date : November 28, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 100mg Fluorescein disodium
100mg Fluorescein disodium will be mixed with 500mL of Gatorade and taken orally by the participant
Drug: fluorescein sodium
Fluorescein sodium in 500mL Gatorade
Other Name: Fluorescite

Placebo Comparator: Placebo
500mL of Gatorade taken orally by the participant
Drug: Placebo
500mL Gatorade




Primary Outcome Measures :
  1. Percentage of patients with detectable urine fluorescence using an ophtalmoscope equipped with a cobalt blue filter [ Time Frame: Up to 24 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Willing and able to comply with visits and study procedures.
  • Healthy males and females between the age of 18 and 55.
  • Female subjects are eligible to participate if they are not pregnant, breastfeeding and at least one of the following conditions apply:

    • Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective (based on the investigator's judgment) for 28 days before/after study drug administration.
    • Is not of WOCBP (Postmenopausal and/or surgically sterile)
  • Male subjects must use effective birth control methods and must not donate sperm until 2 weeks after treatment.

Exclusion Criteria:

  • Staff members involved in the conduct of the study or their family members or site staff members supervised by the investigator. Subjects who are UPTru or Medicor employees, including their family members, directly involved in the conduct of the study are also not eligible to participate.
  • Participants involved in any other study using an investigational product within 30 days or 5 half-lives (if known) prior to screening.
  • Participants with any history of the following conditions:

    • Known history of allergy (such as food or drug-induced urticaria, asthma, eczema or allergic rhinitis) or known allergy to fluorescein disodium or any component of FluoresciteTM or GatoradeTM.
    • Jaundice, bronchial asthma, cirrhosis, uncontrolled diabetes (HbA1c ≥ 7.0), renal failure (calculated creatinine clearance of < 35 mL/min), cancer, HIV or hepatitis B/C.
  • Participants with a life expectancy of fewer than 5 years.
  • In the opinion of the investigator, any clinically significant abnormal ECG, vitals or laboratory result during screening that could put the participant at risk or affect the results of the study.
  • Any concomitant medication that could potentially interact with the study drug or affect the results of the study (based on the investigator's opinion).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04071080


Locations
Layout table for location information
Canada, Ontario
Medicor Research Inc.
Sudbury, Ontario, Canada, P3A 1W8
Sponsors and Collaborators
UpTru Inc.
Medicor Research Inc.
Layout table for additonal information
Responsible Party: UpTru Inc.
ClinicalTrials.gov Identifier: NCT04071080    
Other Study ID Numbers: PH1.20180001
First Posted: August 28, 2019    Key Record Dates
Last Update Posted: January 6, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes